Literature DB >> 34120235

Ultrasound-based radiomics score: a potential biomarker for the prediction of progression-free survival in ovarian epithelial cancer.

Feng Lin1, Li Lan2, Fei Yao3, Jie Ding3, Zhangyong Hu3, Mengting Cai3, Jinjin Liu3, Xiaowan Huang4, Ruru Zheng4.   

Abstract

PURPOSE: More than 80% of patients with ovarian epithelial cancer (OEC) show complete remission after initial treatment but eventually experience recurrence of the disease. This study aimed to develop a radiomics signature to identify a new prognostic indicator based on preoperative ultrasound imaging.
METHODS: A total of 111 patients with OEC who underwent transvaginal ultrasound before surgery were included. Of these, 76 were divided into the training cohort and 35 into the test cohort. We defined the region of interest (ROI) of the tumor by manually drawing the tumor contour on the ultrasound image of the lesion. The radiomics features were extracted from ultrasound images. The radiomics score (Rad-Score) was constructed using the least absolute shrinkage and selection operator (LASSO) analysis and Cox regression. Combined with the ultrasound radiomics features, significant clinical variables were also used to establish predictive models for 5-year progression-free survival (PFS) prediction. The efficiency of the model was evaluated using the area under the curve (AUC). Kaplan-Meier analysis was used to evaluate the association between the Rad-Score and PFS.
RESULTS: The combined model was superior to the clinical and Rad-Score models in estimating 5-year PFS and achieved an AUC of 0.868 (95%CI 0.766-0.971) in the training cohort. The Rad-Score was negatively correlated with prognosis in the training and test cohorts.
CONCLUSIONS: The combined model that incorporated both clinical parameters and ultrasound radiomics features achieved a good prognosis in patients with OEC, which might aid clinical decision-making.

Entities:  

Keywords:  Ovarian cancer; Progression-free survival; Radiomics; Ultrasonography

Year:  2021        PMID: 34120235     DOI: 10.1007/s00261-021-03163-z

Source DB:  PubMed          Journal:  Abdom Radiol (NY)


  5 in total

1.  Significance of Pretreatment C-Reactive Protein, Albumin, and C-Reactive Protein to Albumin Ratio in Predicting Poor Prognosis in Epithelial Ovarian Cancer Patients.

Authors:  Naoko Komura; Seiji Mabuchi; Kotaro Shimura; Mahiru Kawano; Yuri Matsumoto; Tadashi Kimura
Journal:  Nutr Cancer       Date:  2020-08-24       Impact factor: 2.900

2.  Comparison of different nutritional assessments and body-composition measurements in detecting malnutrition among gynecologic cancer patients.

Authors:  Brenda Laky; Monika Janda; Geoffrey Cleghorn; Andreas Obermair
Journal:  Am J Clin Nutr       Date:  2008-06       Impact factor: 7.045

3.  Clinical-radiomics Nomogram for Risk Estimation of Early Hematoma Expansion after Acute Intracerebral Hemorrhage.

Authors:  Qian Chen; Dongqin Zhu; Jinjin Liu; Mingyue Zhang; Haoli Xu; Yilan Xiang; Chenyi Zhan; Yong Zhang; Shengwei Huang; Yunjun Yang
Journal:  Acad Radiol       Date:  2020-03-29       Impact factor: 3.173

4.  Quantitative ultrasound radiomics in predicting response to neoadjuvant chemotherapy in patients with locally advanced breast cancer: Results from multi-institutional study.

Authors:  Daniel DiCenzo; Karina Quiaoit; Kashuf Fatima; Divya Bhardwaj; Lakshmanan Sannachi; Mehrdad Gangeh; Ali Sadeghi-Naini; Archya Dasgupta; Michael C Kolios; Maureen Trudeau; Sonal Gandhi; Andrea Eisen; Frances Wright; Nicole Look Hong; Arjun Sahgal; Greg Stanisz; Christine Brezden; Robert Dinniwell; William T Tran; Wei Yang; Belinda Curpen; Gregory J Czarnota
Journal:  Cancer Med       Date:  2020-06-29       Impact factor: 4.452

  5 in total
  2 in total

1.  Ultrasound radiomics model-based nomogram for predicting the risk Stratification of gastrointestinal stromal tumors.

Authors:  Minling Zhuo; Jingjing Guo; Yi Tang; Xiubin Tang; Qingfu Qian; Zhikui Chen
Journal:  Front Oncol       Date:  2022-08-26       Impact factor: 5.738

2.  MRI radiomics predicts progression-free survival in prostate cancer.

Authors:  Yushan Jia; Shuai Quan; Jialiang Ren; Hui Wu; Aishi Liu; Yang Gao; Fene Hao; Zhenxing Yang; Tong Zhang; He Hu
Journal:  Front Oncol       Date:  2022-08-30       Impact factor: 5.738

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.